2023
Novel Radiotracers for Molecular Imaging of Myocardial Inflammation: an Update Focused on Clinical Translation of Non-18F-FDG Radiotracers
Shi T, Miller E. Novel Radiotracers for Molecular Imaging of Myocardial Inflammation: an Update Focused on Clinical Translation of Non-18F-FDG Radiotracers. Current Cardiovascular Imaging Reports 2023, 16: 1-9. PMID: 36926261, PMCID: PMC9996562, DOI: 10.1007/s12410-023-09574-4.Peer-Reviewed Original ResearchCardiac sarcoidosisMyocardial inflammatory diseaseDisease activityImmunomodulatory therapyInflammatory cardiomyopathyMyocardial inflammationInflammatory diseasesPrognostic performanceReviewThe purposeNovel radiotracersMyocarditisSarcoidosisTherapy guidanceInflammationMolecular featuresRadiotracerClinical translationMolecular imagingMolecular mechanismsHigh specificityCardiomyopathyImproved mechanistic insightsPathogenesisTherapyDisease
2021
Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients with sarcoid cardiomyopathy
Higgins AY, Annapureddy AR, Wang Y, Minges KE, Bellumkonda L, Lampert R, Rosenfeld LE, Jacoby DL, Curtis JP, Miller EJ, Freeman JV. Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients with sarcoid cardiomyopathy. American Heart Journal 2021, 246: 21-31. PMID: 34968442, DOI: 10.1016/j.ahj.2021.12.011.Peer-Reviewed Original ResearchConceptsNon-ischemic cardiomyopathyAtrial fibrillation/flutterChronic lung diseaseCardiac sarcoidosisHeart failureCS patientsNICM patientsICD implantationLung diseaseNew York Heart Association class III heart failureNational Cardiovascular Data Registry ICD RegistryNYHA class IV heart failureClass III heart failureClass IV heart failureImplantable cardioverter defibrillator implantationKaplan-Meier survival curvesCox proportional hazards modelPredictors of mortalityCardioverter-defibrillator implantationVentricular ejection fractionMultivariable logistic regressionPrior ventricular arrhythmiasProportional hazards modelRate of deathTime of implantationPotential novel imaging targets of inflammation in cardiac sarcoidosis
Park J, Young BD, Miller EJ. Potential novel imaging targets of inflammation in cardiac sarcoidosis. Journal Of Nuclear Cardiology 2021, 29: 2171-2187. PMID: 34734365, DOI: 10.1007/s12350-021-02838-w.Peer-Reviewed Original ResearchConceptsCardiac sarcoidosisFDG-PET imagingPositron emission tomographyF-fluorodeoxyglucose positron emission tomographyNon-caseating granulomatous inflammationGranulomatous inflammationHigh morbiditySarcoid granulomasInflammatory diseasesPathognomonic featuresInflammationEmission tomographySarcoidosisMolecular targetsImaging targetsImagingMorbidityGranulomasMortalityDiseaseCytokine Signaling and Matrix Remodeling Pathways Associated with Cardiac Sarcoidosis Disease Activity Defined Using FDG PET Imaging
Young BD, Moreland H, Oatmen KE, Freeburg LA, Shahab Z, Herzog E, Miller EJ, Spinale FG. Cytokine Signaling and Matrix Remodeling Pathways Associated with Cardiac Sarcoidosis Disease Activity Defined Using FDG PET Imaging. International Heart Journal 2021, 62: 21-164. PMID: 34544982, DOI: 10.1536/ihj.21-164.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkersCase-Control StudiesCytokinesEvaluation Studies as TopicFemaleFluorodeoxyglucose F18Heart DiseasesHumansImmunosuppressive AgentsInflammationMaleMatrix Metalloproteinase InhibitorsMatrix MetalloproteinasesMiddle AgedPositron-Emission TomographyProspective StudiesRadiopharmaceuticalsReceptors, Interleukin-2Receptors, Tumor Necrosis FactorRisk AssessmentSarcoidosisSeverity of Illness IndexTumor Necrosis Factor-alphaVascular Endothelial Growth Factor AConceptsTumor necrosis factorSoluble cytokine receptorsCardiac sarcoidosisCS patientsMatrix metalloproteinasePlasma MMP-9 levelsFluorodeoxyglucose positron emission tomographyPlasma tumor necrosis factorAnti-inflammatory regimensBiopsy-confirmed sarcoidosisReferent control valuesSarcoidosis disease activityVascular endothelial growth factor receptorHeart failure therapySoluble TNF receptorsEndothelial growth factor receptorMMP-9 levelsSpecific inflammatory pathwaysFDG-PET imagingEndogenous MMP inhibitorsCytokine receptorsPositron emission tomographyCytokine receptor profilesGrowth factor receptorSIL-2RNon-steroidal treatment of cardiac sarcoidosis: A systematic review
Gallegos C, Oikonomou EK, Grimshaw A, Gulati M, Young BD, Miller EJ. Non-steroidal treatment of cardiac sarcoidosis: A systematic review. IJC Heart & Vasculature 2021, 34: 100782. PMID: 33997256, PMCID: PMC8105294, DOI: 10.1016/j.ijcha.2021.100782.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsNon-steroidal treatmentSteroid-sparing agentCardiac sarcoidosisSafety profileSystematic reviewCases of CSDisease-modifying antirheumatic agentsManagement of CSActive cardiac sarcoidosisAnti-inflammatory managementAverage corticosteroid doseHigher-line treatmentsMaintenance steroid doseFirst-line treatmentSide effect profileSteroid-sparing therapiesInception of databasesLong-term useCorticosteroid doseSteroid doseBiologic DMARDsImmunosuppressive therapyTreatment initiationEffect profileImmunosuppressive agentsArrhythmias in Cardiac Sarcoidosis Bench to Bedside
Rosenfeld LE, Chung MK, Harding CV, Spagnolo P, Grunewald J, Appelbaum J, Sauer WH, Culver DA, Joglar JA, Lin BA, Jellis CL, Dickfeld TM, Kwon DH, Miller EJ, Cremer PC, Bogun F, Kron J, Bock A, Mehta D, Leis P, Siontis KC, Kaufman ES, Crawford T, Zimetbaum P, Zishiri ET, Singh JP, Ellenbogen KA, Chrispin J, Quadri S, Vincent LL, Patton KK, Kalbfleish S, Callahan TD, Murgatroyd F, Judson MA, Birnie D, Okada DR, Maulion C, Bhat P, Bellumkonda L, Blankstein R, Cheng RK, Farr MA, Estep JD. Arrhythmias in Cardiac Sarcoidosis Bench to Bedside. Circulation Arrhythmia And Electrophysiology 2021, 14: e009203. PMID: 33591816, PMCID: PMC8142901, DOI: 10.1161/circep.120.009203.BooksConceptsCardiac sarcoidosisF-fluorodeoxyglucose positron emission tomography scansPositron emission tomography scanCardiac magnetic resonance imagingMultiorgan granulomatous diseaseEmission tomography scanCase-based reviewDisease mechanismsUse of pacemakersMagnetic resonance imagingNew diagnostic testsLife-saving importanceExtracardiac sarcoidosisAssociated arrhythmiasHeart failureVentricular tachyarrhythmiasConduction abnormalitiesOptimal careTreatment optionsGranulomatous diseaseTomography scanEarly diagnosisUncertain causeDiagnostic criteriaResonance imaging
2019
Repeatability and Optimization of FDG Positron Emission Tomography for Evaluation of Cardiac Sarcoidosis
Alvi RM, Young BD, Shahab Z, Pan H, Winkler J, Herzog E, Miller EJ. Repeatability and Optimization of FDG Positron Emission Tomography for Evaluation of Cardiac Sarcoidosis. JACC Cardiovascular Imaging 2019, 12: 1284-1287. PMID: 30846271, DOI: 10.1016/j.jcmg.2019.01.011.Peer-Reviewed Original ResearchSURVIVAL FOLLOWING IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR IMPLANTATION IN PATIENTS WITH CARDIAC SARCOIDOSIS
Higgins A, Annapureddy A, Wang Y, Minges K, Lampert R, Rosenfeld L, Jacoby D, Curtis J, Miller E, Freeman J. SURVIVAL FOLLOWING IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR IMPLANTATION IN PATIENTS WITH CARDIAC SARCOIDOSIS. Journal Of The American College Of Cardiology 2019, 73: 306. DOI: 10.1016/s0735-1097(19)30914-3.Peer-Reviewed Original ResearchREPRODUCIBILITY AND OPTIMIZATION OF 18-FLUORO-DEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY FOR EVALUATION OF CARDIAC SARCOIDOSIS
Alvi R, Young B, Shahab Z, Pan H, Winkler J, Herzog E, Miller E. REPRODUCIBILITY AND OPTIMIZATION OF 18-FLUORO-DEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY FOR EVALUATION OF CARDIAC SARCOIDOSIS. Journal Of The American College Of Cardiology 2019, 73: 1659. DOI: 10.1016/s0735-1097(19)32265-x.Peer-Reviewed Original ResearchUsing FDG-PET to guide targeted cardiac magnetic resonance imaging in patients with suspected cardiac sarcoidosis
Sharp MB, Soufer A, Abdelmessih M, Rosenfeld LE, Baldassarre LA, Miller EJ. Using FDG-PET to guide targeted cardiac magnetic resonance imaging in patients with suspected cardiac sarcoidosis. Journal Of Nuclear Cardiology 2019, 27: 688-690. PMID: 30737635, DOI: 10.1007/s12350-019-01640-z.Peer-Reviewed Original ResearchChapter 9 Cardiac Sarcoidosis Questions for the Clinician
Varghese M, Shahab Z, Miller E. Chapter 9 Cardiac Sarcoidosis Questions for the Clinician. 2019, 105-113. DOI: 10.1016/b978-0-323-54429-0.00009-4.ChaptersCardiac sarcoidosisMagnetic resonance imagingImplantable cardiac defibrillator placementManagement of CSTreatment of CSDiagnosis of CSFluorodeoxyglucose positron emission tomographyCardiac magnetic resonance imagingNuances of treatmentUse of immunosuppressionPositron emission tomographySymptom reviewDefibrillator placementDiagnostic consensusMultiple guidelinesMultidisciplinary teamResonance imagingEmission tomographySelect groupDiagnosisControversial areasElectrocardiogramFurther testingTreatmentImmunosuppression
2018
Specific Pro-Inflammatory Signaling Pathways are Induced in Patients with Cardiac Sarcoidosis; Potential Prognostic/Therapeutic Applications
Young B, Oatmen K, Freeburg L, Zellars K, Sapp A, Herzog E, Miller E, Spinale F. Specific Pro-Inflammatory Signaling Pathways are Induced in Patients with Cardiac Sarcoidosis; Potential Prognostic/Therapeutic Applications. Journal Of Cardiac Failure 2018, 24: s10. DOI: 10.1016/j.cardfail.2018.07.033.Peer-Reviewed Original ResearchCardiac sarcoidosisCardiac inflammationSarcoid patientsReceptor levelsEpidermal growth factorNormal subjectsSoluble tumor necrosis factor receptor IITumor necrosis factor receptor IIFluorodeoxyglucose positron emission tomographyPro-inflammatory signaling pathwaysAnti-inflammatory regimensMethods Plasma samplesHeart failure therapySoluble receptor levelsSpecific inflammatory pathwaysSpecific therapeutic targetingInflammatory signaling cascadesSpecific therapeutic targetsPositron emission tomographyCytokine receptor profilesCardiac involvementFailure therapyPrognostic valueTreatment regimensInflammatory pathwaysA joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology
Slart RHJA, Glaudemans AWJM, Lancellotti P, Hyafil F, Blankstein R, Schwartz RG, Jaber WA, Russell R, Gimelli A, Rouzet F, Hacker M, Gheysens O, Plein S, Miller EJ, Dorbala S, Donal E, Group D. A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. Journal Of Nuclear Cardiology 2018, 25: 298-319. PMID: 29043557, DOI: 10.1007/s12350-017-1043-4.Peer-Reviewed Original ResearchMeSH KeywordsBiopsyCardiologyCardiomyopathiesDiagnostic ImagingEchocardiographyEuropeFluorodeoxyglucose F18HumansImage Processing, Computer-AssistedInflammationMyocardial Perfusion ImagingNuclear MedicinePositron-Emission TomographyPrognosisRadionuclide ImagingReproducibility of ResultsSarcoidosisSocieties, MedicalTomography, X-Ray ComputedUnited States
2017
A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology
Slart R, Glaudemans A, Lancellotti P, Hyafil F, Blankstein R, Schwartz R, Jaber W, Russell R, Gimelli A, Rouzet F, Hacker M, Gheysens O, Plein S, Miller E, Dorbala S, Donal E, Sciagra R, Bucerius J, Verberne H, Lindner O, Übleis C, Agostini D, Signore A, Edvardsen T, Neglia D, Beanlands R, Di Carli M, Chareonthaitawee P, Dilsizian V, Soman P, Habib G, Delgado V, Cardim N, Cosyns B, Flachskampf F, Gerber B, Haugaa K, Lombardi M, Masci P. A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. European Heart Journal - Cardiovascular Imaging 2017, 18: 1073-1089. PMID: 28984894, DOI: 10.1093/ehjci/jex146.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsCardiac Imaging TechniquesCardiologyCardiomyopathiesEuropeFemaleHumansMagnetic Resonance ImagingMaleMultimodal ImagingMyocardial Perfusion ImagingNuclear MedicinePositron Emission Tomography Computed TomographyPractice Guidelines as TopicRadionuclide ImagingSarcoidosisSocieties, MedicalUnited StatesConceptsCardiac sarcoidosisEuropean AssociationManagement of patientsCardiovascular magnetic resonanceMyocardial perfusion imagingPositron emission tomographyJoint position paperInfection committeeMulti-center dataClinical trialsSarcoidosisPerfusion imagingEmission tomographyCardiovascular imagingPosition statementAmerican SocietyNuclear cardiologyPosition paperNuclear medicineMagnetic resonanceAssociationCorrect useImagingEchocardiographyInflammation
2016
The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis
Ahmadian A, Pawar S, Govender P, Berman J, Ruberg FL, Miller EJ. The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis. Journal Of Nuclear Cardiology 2016, 24: 413-424. PMID: 27457527, DOI: 10.1007/s12350-016-0490-7.Peer-Reviewed Original ResearchConceptsFDG PET/CTPET/CTFDG uptakeCardiac sarcoidosisFDG PET/CT studiesPET/CT studiesImmunosuppressive treatmentCardiac inflammationPartial responseComplete resolutionImproved outcomesSUV thresholdImmunosuppressionFDG responseCT studiesPatientsCTSarcoidosisFurther studiesQuantitative changesUptakeResponseInflammationSUVmaxCMV
2015
Multimodality Imaging of Cardiac Sarcoidosis
Blankstein R, Miller E. Multimodality Imaging of Cardiac Sarcoidosis. 2015, 51-72. DOI: 10.1007/978-3-319-14624-9_7.ChaptersCardiac sarcoidosisCardiac MRIImaging testsHigh negative predictive valueExtra-cardiac diseasePreferred imaging testLate gadolinium enhancementFuture adverse eventsNegative predictive valueActive myocardial inflammationImmunosuppressive therapyCardiac involvementMyocardial inflammationAdverse eventsExcellent prognosisClinical criteriaReliable reference standardGadolinium enhancementSarcoidosisPredictive valueMultimodality imagingPatientsTherapyMRIDiagnosis
2014
Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis
Ahmadian A, Brogan A, Berman J, Sverdlov AL, Mercier G, Mazzini M, Govender P, Ruberg FL, Miller EJ. Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. Journal Of Nuclear Cardiology 2014, 21: 925-939. PMID: 24879453, DOI: 10.1007/s12350-014-9901-9.Peer-Reviewed Original ResearchMeSH KeywordsFemaleFluorodeoxyglucose F18Heart DiseasesHumansImage EnhancementImage Interpretation, Computer-AssistedMaleMiddle AgedMultimodal ImagingMyocardial Perfusion ImagingPositron-Emission TomographyRadiopharmaceuticalsReproducibility of ResultsRetrospective StudiesSarcoidosisSensitivity and SpecificityTomography, X-Ray ComputedConceptsFDG PET/CTPET/CTCardiac sarcoidosisStandardized uptake valueMyocardial perfusion imagingClinical eventsPerfusion imagingCardiac FDG PET/CTAdverse clinical eventsOnly independent predictorNegative control studyCS correlatesImmunosuppressive treatmentPrednisone treatmentImmunosuppression treatmentIndependent predictorsFDG uptakeOncologic indicationsPerfusion defectsNegative studiesRepeat examinationLow EFUptake valueControl studyMultivariate analysis